Profile data is unavailable for this security.
About the company
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-21.10m
- Incorporated2020
- Employees13.00
- LocationNuvectis Pharma Inc1 Bridge Plaza, Suite 275FORT LEE 07024United StatesUSA
- Phone+1 (360) 837-7232
- Fax+1 (302) 636-5454
- Websitehttps://nuvectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences Inc | 21.48m | -45.61m | 117.39m | 65.00 | -- | 3.38 | -- | 5.46 | -9.32 | -9.32 | 4.28 | 5.47 | 0.2362 | -- | 125.62 | 330,476.90 | -50.15 | -39.69 | -69.22 | -44.03 | -- | -- | -212.33 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 117.77m | 31.00 | -- | 2.20 | -- | 177.10 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| INmune Bio Inc | 85.00k | -37.74m | 118.18m | 11.00 | -- | 2.83 | -- | 1,390.34 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -40.68m | 118.19m | 25.00 | -- | 3.82 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 119.08m | -- | 6.90 | 0.241 | 61.58 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 119.23m | 93.00 | 8.26 | 1.26 | 6.60 | 211.78 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 123.37m | 140.00 | -- | 41.23 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 125.25m | 143.00 | -- | 0.5327 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Puma Biotechnology Inc | 219.14m | 8.72m | 125.56m | 185.00 | 13.99 | 2.56 | 6.19 | 0.573 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 125.91m | 13.00 | -- | 10.10 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Agenus Inc | 159.63m | -223.67m | 129.22m | 389.00 | -- | -- | -- | 0.8095 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 130.19m | 246.00 | -- | -- | -- | 0.4225 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 130.36m | 102.00 | -- | 1.84 | -- | 1,095.48 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 134.54m | 112.00 | -- | -- | -- | 5.44 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 135.75m | 111.00 | -- | 0.6328 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 135.99m | 64.00 | -- | 1.51 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Nuvectis Pharma Inc's reporting currency: US Dollar USD
5.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 249.28k | 1.34% |
| Baldwin Brothers LLCas of 30 Jun 2024 | 168.63k | 0.90% |
| Millennium Management LLCas of 30 Jun 2024 | 119.46k | 0.64% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 76.83k | 0.41% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 74.50k | 0.40% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 61.57k | 0.33% |
| Geode Capital Management LLCas of 30 Jun 2024 | 53.23k | 0.29% |
| GSA Capital Partners LLPas of 30 Jun 2024 | 48.34k | 0.26% |
| J. M. Forbes & Co. LLPas of 30 Jun 2024 | 47.42k | 0.25% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 46.22k | 0.25% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
